Stanley Lipkowitz

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

(2023)10.1158/2767-9764.22545575

Top 100%

0DataRank

Top 100%0 citations

Lídia Hernandez, Emily M.J. Fennell, Manjari Kundu, Donna Voeller, Raj Chari +12 more

Papers

Driven by 45 papers — median percentile 0. Top paper: “A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma”.

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

The Oncologist(2023)10.1093/oncolo/oyad164

N/A

0.512DataRank · unranked

12 citations

Yoshimi Endo Greer, Sarah M. Jenkins, Margaret E. Gatti‐Mays, Nicole Houston, Sunmin Lee +11 more

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Cancer Medicine(2025)10.1002/cam4.71220

N/A

0.104DataRank · unranked

1 citations

Ashley Cimino‐Mathews, Stanley Lipkowitz, Min-Jung Lee, Jayakumar R. Nair, B. Brooke Solarz +9 more

Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps2572

N/A

0DataRank · unranked

0 citations

Seth M. Steinberg, DeeDee Kay Smart, Mark R. Gilbert, Terri S. Armstrong, Eric Burton +9 more

Rare Breast Cancer Subtypes

Current Oncology Reports(2021)10.1007/s11912-021-01048-4

N/A

0DataRank · unranked

48 citations

Megan E. Kachur, Kamil Rechache, J. Mitchell Wells, Stanley Lipkowitz, Sarah M. Jenkins

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in Oncology(2021)10.3389/fonc.2020.581801

N/A

0DataRank · unranked

22 citations

Sofia R. Gameiro, Yohei Ozawa, Karin M. Knudson, Kristin C. Hicks, Claudia Palena +10 more

Sinularamides A–G, Terpenoid-Derived Spermidine and Spermine Conjugates with Casitas B-Lineage Lymphoma Proto-Oncogene B (Cbl-b) Inhibitory Activities from a Sinularia sp. Soft Coral

Journal of Natural Products(2021)10.1021/acs.jnatprod.1c00367

N/A

0DataRank · unranked

7 citations

Dongdong Wang, Brice A. P. Wilson, Donna Voeller, Heidi R. Bokesch, Emily A. Smith +4 more

Agelasine Diterpenoids and Cbl-b Inhibitory Ageliferins from the Coralline Demosponge Astrosclera willeyana

Marine Drugs(2021)10.3390/md19070361

N/A

0DataRank · unranked

12 citations

Dongdong Wang, Brice A. P. Wilson, Unwoo Kang, Heidi R. Bokesch, Emily A. Smith +7 more

In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors

SLAS DISCOVERY(2021)10.1177/24725552211000675

N/A

0DataRank · unranked

6 citations

Donna Voeller, Emily A. Smith, Antony Wamiru, Ekaterina I. Goncharova, Gang Liu +3 more

Characterization of TR ‐107, a novel chemical activator of the human mitochondrial protease ClpP

Pharmacology Research & Perspectives(2022)10.1002/prp2.993

N/A

0DataRank · unranked

43 citations

Lucas J. Aponte‐Collazo, Joshua D. Wynn, Kristina Drizyte‐Miller, Elisa Leung, Yoshimi Endo Greer +12 more

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Cells(2022)10.3390/cells11233717

N/A

0DataRank · unranked

42 citations

Yoshimi Endo Greer, Jennifer Dine, Stanley Lipkowitz, Manjari Kundu

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

Med(2022)10.1016/j.medj.2022.11.001

N/A

0DataRank · unranked

42 citations

Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh, Eden Maimon +26 more

Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Cancer Research Communications(2022)10.1158/2767-9764.crc-22-0142

N/A

0DataRank · unranked

31 citations

Lídia Hernandez, Emily M.J. Fennell, Manjari Kundu, Donna Voeller, Raj Chari +12 more

Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density

Redox Biology(2022)10.1016/j.redox.2022.102529

N/A

0DataRank · unranked

24 citations

Lisa A. Ridnour, Robert Y.S. Cheng, Abigail J. Walke, Noémi Kedei, Dibyangana D. Bhattacharyya +21 more

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1893

N/A

0DataRank · unranked

21 citations

Franklin Ning, Anna Duemler, Timothy G. Myers, Kathryn Trewhitt, Irene Ekwede +24 more

Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-B

Organic Letters(2022)10.1021/acs.orglett.2c03922

N/A

0DataRank · unranked

9 citations

Dong‐Hao Li, Brice A. P. Wilson, Kalina Ranguelova, Masoumeh Dalilian, Emily A. Smith +9 more

Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth

Journal of Biological Chemistry(2022)10.1016/j.jbc.2022.102766

N/A

0DataRank · unranked

8 citations

Mariya Liyasova, Soumya Korrapati, Xu Zhang, Shashikala Ratnayake, Qingrong Chen +9 more

Late‐onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma

American Journal of Medical Genetics Part A(2022)10.1002/ajmg.a.62761

N/A

0DataRank · unranked

2 citations

Anne Slavotinek, Thomas N. Darling, Stanley Lipkowitz, Frederic G. Barr, Pamela N. Münster +3 more

SMALL MOLECULE CLPP AGONISTS INDUCE SENESCENCE AND ALTER TRAIL-MEDIATED APOPTOTIC RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.07.11.499620

N/A

0DataRank · unranked

3 citations

Emily M.J. Fennell, Michael P. East, Thomas S.K. Gilbert, Paul R. Graves, Hani Ashamalla +5 more

Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.14.480426

N/A

0DataRank · unranked

1 citations

Lucas J. Aponte‐Collazo, Joshua D. Wynn, Kristina Drizyte‐Miller, Elisa Leung, Yoshimi Endo Greer +12 more

Mitochondrial Matrix Protease ClpP Agonists inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.18.484947

N/A

0DataRank · unranked

0 citations

Lídia Hernandez, Emily M.J. Fennell, Donna Voeller, Raj Chari, Sam Gilbert +7 more

Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0208

N/A

0DataRank · unranked

42 citations

Stanley Lipkowitz, Nicole G. Campos, Mark Schiffman, John T. Schiller, Neal D. Freedman +2 more

Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer

Cancers(2023)10.3390/cancers15071936

N/A

0DataRank · unranked

33 citations

Yoshimi Endo Greer, David Wisniewski, Sarah Weltz, Manjari Kundu, Donna Voeller +2 more

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-0855

N/A

0DataRank · unranked

23 citations

Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu +22 more

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1553

N/A

0DataRank · unranked

2 citations

Gal Dinstag, Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh +15 more

Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.21.572867

N/A

0DataRank · unranked

2 citations

Robert Y.S. Cheng, William F. Heinz, Milind Pore, Ana L. González, Elise L. Femino +22 more

Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer

Research Square(2023)10.21203/rs.3.rs-3399502/v1

N/A

0DataRank · unranked

1 citations

Kei Kudo, Yoshimi Endo Greer, Teruhiko Yoshida, Brittney S. Harrington, Soumya Korrapati +6 more

NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER-Breast Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.21.572859

N/A

0DataRank · unranked

1 citations

William F. Heinz, Robert Y.S. Cheng, Adelaide L. Wink, Noémi Kedei, Milind Pore +21 more

Supplementary Table S2 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

(2023)10.1158/2767-9764.22545575

Top 100%

0DataRank

Top 100%0 citations

Lídia Hernandez, Emily M.J. Fennell, Manjari Kundu, Donna Voeller, Raj Chari +12 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0DataRank · unranked

42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer

Cancer Gene Therapy(2024)10.1038/s41417-024-00748-w

N/A

0DataRank · unranked

11 citations

Yoshimi Endo Greer, Teruhiko Yoshida, Brittney S. Harrington, Soumya Korrapati, Yusuke Shibuya +6 more

Adjuvant COX inhibition augments STING signaling and cytolytic T cell infiltration in irradiated 4T1 tumors

JCI Insight(2024)10.1172/jci.insight.165356

N/A

0DataRank · unranked

8 citations

Robert Y.S. Cheng, Noémi Kedei, Veena Somasundaram, Dibyangana D. Bhattacharyya, Debashree Basudhar +25 more

TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.07.19.604341

N/A

0DataRank · unranked

3 citations

Yoshimi Endo Greer, Alexei Lobanov, Lisa A. Ridnour, Renee N. Donahue, Yeap Ng +11 more

Targeting Metabolic Vulnerability by Combining NAMPT Inhibitors and Disulfiram for Treatment of Recurrent Ovarian Cancer

Research Square(2024)10.21203/rs.3.rs-4150814/v1

N/A

0DataRank · unranked

0 citations

Kei Kudo, Daniel R. Crooks, Yoshimi Endo Greer, Ye Yang, Jeffrey Brender +10 more

TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells

Cancer Letters(2025)10.1016/j.canlet.2025.217692

N/A

0DataRank · unranked

10 citations

Yoshimi Endo Greer, Alexei Lobanov, Lisa A. Ridnour, Renee N. Donahue, Yeap Ng +12 more

A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models

Clinical & Experimental Metastasis(2025)10.1007/s10585-025-10366-x

N/A

0DataRank · unranked

6 citations

Samiur Rahman, Alex Man Lai Wu, Kristine A. Isanogle, Christina M. Robinson, Dinesh Kumar +8 more

Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER– breast cancer

JCI Insight(2025)10.1172/jci.insight.193091

N/A

0DataRank · unranked

5 citations

Robert Y.S. Cheng, William F. Heinz, Milind Pore, Ana L. González, Elise L. Femino +22 more

Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer

Cell Death and Disease(2025)10.1038/s41419-025-07672-3

N/A

0DataRank · unranked

4 citations

Yoshimi Endo Greer, Daniel R. Crooks, Ye Yang, Jeffrey Brender, Teruhiko Yoshida +10 more

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Oncogene(2025)10.1038/s41388-025-03634-3

N/A

0DataRank · unranked

2 citations

Donna Voeller, Yonit A. Addissie, Sachin Kumar Deshmukh, Sharon Wu, Maryam B. Lustberg +7 more

Revisiting surrogacy of pathological complete response for long-term survival in triple-negative breast cancer

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf022

N/A

0DataRank · unranked

4 citations

Zao Zhang, Ryota Sato, Stanley Lipkowitz, Takeo Fujii, Toru Yoshino

Proteogenomic characterization of invasive breast tumors in young women

npj Breast Cancer(2025)10.1038/s41523-025-00793-0

N/A

0DataRank · unranked

3 citations

Jianfang Liu, Anthony R. Soltis, Nicholas W. Bateman, Qingrong Chen, Lori A. Sturtz +70 more

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.03.657674

N/A

0DataRank · unranked

0 citations

Donna Voeller, Yonit A. Addissie, Sachin Kumar Deshmukh, Sharon Wu, Maryam B. Lustberg +7 more

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1

N/A

0DataRank · unranked

0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056

N/A

0DataRank · unranked

224 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax

Research Square(2025)10.21203/rs.3.rs-7682325/v1

N/A

0DataRank · unranked

0 citations

Sabrina Daglish, Owen G Canterbury, Paul R. Graves, Sarah Carter, Sydney Beese +18 more

Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6038

N/A

0DataRank · unranked

7 citations

Daniel An, Ann McCoy, Elise C. Kohn, Christina M. Annunziata, Kathryn Trewhitt +4 more

Stanley Lipkowitz

Indexed papers

Top data-sharing exemplar

Papers